Serplulimab, which received a license in China in March 2022, was similar to other PD‐1 monoclonal antibodies in the binding region of PD‐L1, preventing PD‐1 from interacting with ligands PD‐L1 and PD‐L2, and offering dose‐dependent tumor suppression.40, 41. This evidence concerns the gene PDCD1 and neoplasm.